PMID- 34490101
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210908
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin 
      (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia.
PG  - 701539
LID - 10.3389/fonc.2021.701539 [doi]
LID - 701539
AB  - This real-world, observational study aimed to assess and compare the clinical 
      efficacy and safety of eltrombopag with recombinant human thrombopoietin (rhTPO) 
      in the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with 
      lymphoma. One hundred and fifty-three patients who experienced grade 3 or 4 
      thrombocytopenia after chemotherapy for lymphoma were enrolled, 51 of which were 
      treated with eltrombopag, 50 with rhTPO, and 52 patients with no drug treatment 
      were served as the control group. The lowest platelet level and mean platelet 
      counts at Day 5, Day 7, and Day 10 were significantly higher in both the 
      eltrombopag group (P=.041,.003,.000,.000) and rhTPO group (P=.005,.005,.000,.000) 
      than the control, but there was no difference between treatment with eltrombopag 
      and rhTPO. Similarly, days required for the recovery of platelet counts to 
      >/=50x10(9)/L and >/=75x10(9)/L were not different between the two treatment groups 
      but significantly higher than the control group (P <.05). Rates of bleeding and 
      platelet transfusion were all significantly reduced in patients treated with 
      eltrombopag (P=.031,.032) or rhTPO (P=.017,.009) when compared to the control. 
      Treatment-related adverse events (AEs) were reported in 7 (13.7%) and 6 (12.0%) 
      patients in the eltrombopag and rhTPO groups, respectively, all being mild and 
      transient in nature. In conclusion, both eltrombopag and rhTPO were effective and 
      safe in the treatment of thrombocytopenia after chemotherapy for lymphoma.
CI  - Copyright (c) 2021 Zhu, Yang, Zeng, Li, Guan, Zhou, Wang, Liu, Gao, Qiu, Chen, Li, 
      Zheng, Yuan, Zhang and Pan.
FAU - Zhu, Qiuhua
AU  - Zhu Q
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
FAU - Yang, Shimei
AU  - Yang S
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
FAU - Zeng, Wenbin
AU  - Zeng W
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
FAU - Li, Mingjie
AU  - Li M
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
FAU - Guan, Zebing
AU  - Guan Z
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
FAU - Zhou, Lanlan
AU  - Zhou L
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
FAU - Wang, Hong
AU  - Wang H
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
FAU - Liu, Yanan
AU  - Liu Y
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
FAU - Gao, Yanmin
AU  - Gao Y
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
FAU - Qiu, Shiqiu
AU  - Qiu S
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
FAU - Chen, Chaolun
AU  - Chen C
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
FAU - Li, Huan
AU  - Li H
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
FAU - Zheng, Shanshan
AU  - Zheng S
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
FAU - Yuan, Yuemei
AU  - Yuan Y
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
FAU - Zhang, Hanling
AU  - Zhang H
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
FAU - Pan, Xueyi
AU  - Pan X
AD  - Department of Hematology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangdong, China.
LA  - eng
PT  - Journal Article
DEP - 20210818
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8418194
OTO - NOTNLM
OT  - chemotherapy
OT  - eltrombopag
OT  - lymphoma
OT  - recombinant human thrombopoietin (rhTPO)
OT  - thrombocytopaenia
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/09/08 06:00
MHDA- 2021/09/08 06:01
PMCR- 2021/01/01
CRDT- 2021/09/07 07:45
PHST- 2021/04/28 00:00 [received]
PHST- 2021/07/31 00:00 [accepted]
PHST- 2021/09/07 07:45 [entrez]
PHST- 2021/09/08 06:00 [pubmed]
PHST- 2021/09/08 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.701539 [doi]
PST - epublish
SO  - Front Oncol. 2021 Aug 18;11:701539. doi: 10.3389/fonc.2021.701539. eCollection 
      2021.